Cytonus Therapeutics
Robert Schneider, PhD is New York University’s Albert Sabin Professor of Molecular Pathogenesis, and for seven years until 2020 the Associate Dean for NYU Technology Ventures and Partnerships (the technology, commercialization and therapeutics discovery office of NYU), Professor of Radiation Oncology, and Co-Director of the Breast Cancer Research Program at NYU School of Medicine. Professor Schneider’s research focuses on three major areas: (i) translational regulation of advanced breast cancers and the development of new treatment strategies and therapeutics for advanced cancers; (ii) translational regulation of the immune response and applications in development of immune-oncology therapeutics; and (iii) regulation of adult tissue stem cells and tissue regeneration controlled by targeted mRNA decay and translational regulation.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Cytonus Therapeutics
Cytonus Therapeutics has developed a first-in-class “biologic drone” called the Cargocyte. The Cargocyte is a platform to deliver therapeutics in a precise, controlled, safe and reproducible manner. Cytonus’ innovative approach delivers on the long sought after promises of drug delivery, to deliver the right drug at the right dose to the right tissue.